Skip to Content

Kantrex Side Effects

Generic name: kanamycin

Note: This document contains side effect information about kanamycin. Some of the dosage forms listed on this page may not apply to the brand name Kantrex.

Applies to kanamycin: compounding powder, injectable solution, oral capsule

General

The major toxic effects associated with kanamycin (the active ingredient contained in Kantrex) therapy are ototoxicity and nephrotoxicity. It is considered one of the more toxic aminoglycosides.[Ref]

Nervous system

Nervous system side effects have included neuromuscular blockade, ototoxicity resulting in loss of vestibular function secondary to hair cell damage, and irreversible or partially reversible bilateral hearing loss. Nystagmus, vertigo, nausea, vomiting, and acute Meniere's syndrome are signs of vestibular dysfunction. Cochlear damage may be asymptomatic and may initially manifest as minor changes in audiometric test results at higher frequencies. Aminoglycosides have been associated with acute muscular paralysis, apnea, peripheral neuropathy and encephalopathy (numbness, paresthesia, muscle twitching, seizures), and myasthenia gravis-like syndrome. Neurotoxicity may occur after intrapleural, intraperitoneal, or parenteral administration. Patients with renal impairment may be at a higher risk.[Ref]

Renal

Renal side effects have included nephrotoxicity, albuminuria, presence of red and white cells and granular casts, azotemia, oliguria, and increased serum creatinine and BUN.[Ref]

Dermatologic

Dermatologic reactions have included skin rash.[Ref]

Gastrointestinal

Gastrointestinal side effects have included nausea, vomiting, and diarrhea.[Ref]

Local

Local reactions have included pain at the injection site after intramuscular injection.[Ref]

Metabolic

Metabolic side effects associated with prolonged kanamycin (the active ingredient contained in Kantrex) treatment have included malabsorption syndrome manifested as increased fecal fat, decreased serum carotene, and decreased xylose absorption.[Ref]

References

1. "Product Information. Kanamycin (kanamycin)." Raway Pharmacal Inc, Accord, NY.

2. Peloquin CA, Berning SE, Nitta AT, et al. "Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases." Clin Infect Dis 38 (2004): 1538-44

Medically reviewed by Drugs.com. Last updated on Nov 9, 2020.

More about Kantrex (kanamycin)

Consumer resources

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.